These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 26992393)
41. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282 [TBL] [Abstract][Full Text] [Related]
42. Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis. Pornpaisalsakul K; Songtaweesin WN; Tepmongkol S; Wongharn P; Kawichai S; Suponsilchai V; Anugulruengkitt S; Puthanakit T; J Int AIDS Soc; 2020 Oct; 23(10):e25624. PubMed ID: 33040465 [TBL] [Abstract][Full Text] [Related]
43. Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework. Amico KR; Wallace M; Bekker LG; Roux S; Atujuna M; Sebastian E; Dye BJ; Elharrar V; Grant RM AIDS Behav; 2017 May; 21(5):1361-1375. PubMed ID: 27317411 [TBL] [Abstract][Full Text] [Related]
44. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis. Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366 [TBL] [Abstract][Full Text] [Related]
45. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM; Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682 [TBL] [Abstract][Full Text] [Related]
46. A case study of chewed Truvada Lalley-Chareczko L; Clark D; Zuppa AF; Moorthy G; Conyngham C; Mounzer K; Koenig H Antivir Ther; 2017; 22(7):639-641. PubMed ID: 28260694 [TBL] [Abstract][Full Text] [Related]
47. Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. Amico KR; Marcus JL; McMahan V; Liu A; Koester KA; Goicochea P; Anderson PL; Glidden D; Guanira J; Grant R J Acquir Immune Defic Syndr; 2014 Aug; 66(5):530-7. PubMed ID: 24853306 [TBL] [Abstract][Full Text] [Related]
49. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. Hosek SG; Landovitz RJ; Kapogiannis B; Siberry GK; Rudy B; Rutledge B; Liu N; Harris DR; Mulligan K; Zimet G; Mayer KH; Anderson P; Kiser JJ; Lally M; Brothers J; Bojan K; Rooney J; Wilson CM JAMA Pediatr; 2017 Nov; 171(11):1063-1071. PubMed ID: 28873128 [TBL] [Abstract][Full Text] [Related]
50. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women. Carballo-Diéguez A; Balán IC; Brown W; Giguere R; Dolezal C; Leu CS; Marzinke MA; Hendrix CW; Piper JM; Richardson BA; Grossman C; Johnson S; Gomez K; Horn S; Kunjara Na Ayudhya RP; Patterson K; Jacobson C; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla C; Lama J; McGowan I; Cranston RD PLoS One; 2017; 12(7):e0181607. PubMed ID: 28750059 [TBL] [Abstract][Full Text] [Related]
51. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L; Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274 [TBL] [Abstract][Full Text] [Related]
52. Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities. Chan PA; Mena L; Patel R; Oldenburg CE; Beauchamps L; Perez-Brumer AG; Parker S; Mayer KH; Mimiaga MJ; Nunn A J Int AIDS Soc; 2016; 19(1):20903. PubMed ID: 27302837 [TBL] [Abstract][Full Text] [Related]
53. The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study. Mehrotra ML; Glidden DV; McMahan V; Amico KR; Hosek S; Defechereux P; Mayer KH; Veloso VG; Bekker LG; Avelino-Silva VI; Schechter M; Grant RM AIDS Behav; 2016 Jul; 20(7):1527-34. PubMed ID: 27125241 [TBL] [Abstract][Full Text] [Related]
54. Behavior Change Among HIV-Negative Men Who Have Sex with Men Not Using PrEP in the United States. Goodreau SM; Barry MP; Hamilton DT; Williams AM; Wang LY; Sanchez TH; Katz DA; Delaney KP AIDS Behav; 2024 May; 28(5):1766-1780. PubMed ID: 38411799 [TBL] [Abstract][Full Text] [Related]
55. Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study. Lopes SS; Pericot-Valverde I; Lum PJ; Taylor LE; Mehta SH; Tsui JI; Feinberg J; Kim AY; Norton BL; Page K; Murray-Krezan C; Anderson J; Karasz A; Arnsten J; Moschella P; Heo M; Litwin AH BMC Infect Dis; 2024 Feb; 24(1):251. PubMed ID: 38395747 [TBL] [Abstract][Full Text] [Related]
56. Low daily oral PrEP adherence and low validity of self-report in a randomized trial among PWID in Ukraine. Dumchev K; Kornilova M; Makarenko O; Antoniak S; Liulchuk M; Cottrell ML; Varetska O; Morozova O Int J Drug Policy; 2024 Jan; 123():104284. PubMed ID: 38061223 [TBL] [Abstract][Full Text] [Related]
57. PrEPare for Work: A Pilot Randomized Controlled Trial of an Intervention to Optimize HIV PrEP Outcomes Among Male Sex Workers. Biello KB; Chan PA; Holcomb R; Ndoye CD; Valente PK; Maynard M; Gandhi M; Mayer KH; Mimiaga MJ AIDS Behav; 2023 Oct; 27(10):3294-3305. PubMed ID: 36976389 [TBL] [Abstract][Full Text] [Related]
58. Designing HIV Vaccine Efficacy Trials in the Context of Highly Effective Non-vaccine Prevention Modalities. Janes H; Zhu Y; Brown ER Stat Biosci; 2020 Dec; 12(3):468-494. PubMed ID: 36938334 [TBL] [Abstract][Full Text] [Related]
59. Self-reported and pill count measures of adherence to oral HIV PrEP among female sex workers living in South-Western Uganda. Nakiganda LJ; Grulich AE; Poynten IM; Serwadda D; Bazaale JM; Jin J; Bavinton BR PLoS One; 2022; 17(11):e0277226. PubMed ID: 36355810 [TBL] [Abstract][Full Text] [Related]